Inhibikase Therapeutics Q2 EPS $(0.66) Beats $(0.67) Estimate
Portfolio Pulse from totan@benzinga.com
Inhibikase Therapeutics (NASDAQ:IKT) reported a Q2 EPS of $(0.66), beating the analyst consensus estimate of $(0.67) by 1.49%. This represents a 29.79% improvement over the $(0.94) loss per share from the same period last year.
August 14, 2024 | 8:26 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Inhibikase Therapeutics reported a Q2 EPS of $(0.66), beating the analyst consensus estimate of $(0.67) by 1.49%. This is a significant improvement from the $(0.94) loss per share in the same period last year.
The better-than-expected EPS and significant year-over-year improvement are likely to positively impact the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100